Pharma Industry News

A Pan-cancer View of Immune Cell Activity, Immune Checkpoints, and Tumor Mutational Burden

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/immune

In addition to tumor mutational burden (TMB) and intrinsic subtypes, RNA-based assays are now available for clinical trials to measure immune cell activity in the tumor microenvironment given a tumor specimen. Our lOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]